← Back to headlines
Analysts Reiterate Ratings for Braze and Inhibrx Biosciences
Oppenheimer maintained its rating on Braze following Q2 results, while H.C. Wainwright reiterated a buy rating for Inhibrx Biosciences. These analyst actions reflect continued confidence in the companies' prospects despite market volatility.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Signet Jewelers Raises Profit Forecast After Strong Quarterly Results
45m ago
Nigeria’s Oil Regulator Threatens Permit Revocations for Idle Gas Flare Sites
1h ago
Record Travel Demand Hits Dublin Airport and Portuguese Cruise Industry
1h ago
Corporate Earnings Highlights from Wells Fargo and Goldman Sachs Conferences
1h ago